Telomerase activity in colorectal cancer, prognostic factor and implications in the microsatellite instability pathway

Table 1 Relationship of telomerase activity and MSI with clinicopathological variables of the 97 patients with colorectal carcinoma n (%)

Variable					P	Telomerase		P
		MSS	MSI-L	MSI-H		Positive	Negative
Sex	Men: 51 (52.6)	40 (78.4)	7 (13.7)	4 (7.8)	0.20	46 (90.2)	5 (9.8)	0.44
	Female: 46 (47.4)	41 (89.1)	3 (6.5)	2 (4.3)		44 (95.7)	2 (4.3)
Age	≥ 71 yr: 50 (51.5)	39 (78.0)	5 (10.0)	6 (12.6)	0.03	47 (94.0)	3 (6.0)	0.70
	< 71 yr: 47 (48.5)	42 (89.4)	5 (10.6)	0 (0)		43 (91.5)	4 (8.5)
Dukes stage	A+B: 47 (48.5)	40 (85.1)	4 (8.5)	3 (6.4)	0.90	42 (89.4)	5 (10.6)	0.13
	C: 26 (26.8)	22 (84.6)	1 (3.8)	3 (11.5)		24 (92.3)	2 (7.7)
	D: 24 (24.7)	19 (79.2)	5 (20.8)	0 (0)		24 (100)	0 (0)
Site	Colon: 70 (72.2)	56 (80.0)	8 (11.4)	6 (8.6)	0.08	67 (95.7)	3 (4.3)	0.09
	Rectum: 27 (27.8)	25 (92.6)	2 (7.4)	0 (0)		23 (85.2)	4 (14.8)
Colon site	Proximal: 37 (52.8)	26 (70.3)	5 (13.5)	6 (16.2)	0.01	34 (91.9)	3 (8.1)	0.04
	Distal: 33 (47.2)	30 (92.6)	3 (9.1)	0 (0)		33 (100)	0 (0)
Grade	I: 56 (65.9)	47 (83.9)	6 (10.7)	3 (5.4)	0.32	27 (93.1)	2 (6.9)	1.00
	II + III: 29 (34.1)	22 (75.9)	4 (13.8)	3 (10.3)		52 (92.9)	4 (7.1)
Histological	Adenocarcinoma: 87	72 (82.8)	9 (10.3)	6 (6.9)	0.44	80 (92.0)	7 (8.0)	1.00
	(89.7)	9 (90.0)	1 (10.0)	0 (0)		10 (100)	0 (0)
type	Mucoid: 10 (10.3)
Chemo therapy	Yes: 52 (53.6)	44 (84.6)	6 (11.5)	2 (3.8)	0.50	49 (94.2)	3 (5.8)	0.70
	No: 45 (46.4)	37 (82.2)	4 (8.9)	4 (8.9)		41 (91.1)	4 (8.9)

MSS: absence of microsatellite instability; MSI-L: low instability; MSI-H: high instability. Statistically significant: P < 0.05.